Details for New Drug Application (NDA): 011366
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
NDA 011366 describes KEVEYIS, which is a drug marketed by Xeris and is included in one NDA. It is available from one supplier. Additional details are available on the KEVEYIS profile page.
The generic ingredient in KEVEYIS is dichlorphenamide. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the dichlorphenamide profile page.
The generic ingredient in KEVEYIS is dichlorphenamide. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the dichlorphenamide profile page.
Summary for 011366
| Tradename: | KEVEYIS |
| Applicant: | Xeris |
| Ingredient: | dichlorphenamide |
| Patents: | 0 |
| Formulation / Manufacturing: | see details |
Pharmacology for NDA: 011366
| Mechanism of Action | Carbonic Anhydrase Inhibitors |
Medical Subject Heading (MeSH) Categories for 011366
Suppliers and Packaging for NDA: 011366
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| DARANIDE | dichlorphenamide | TABLET;ORAL | 011366 | NDA | Strongbridge US Inc. | 71090-001 | 71090-001-01 | 100 TABLET in 1 BOTTLE (71090-001-01) |
| KEVEYIS | dichlorphenamide | TABLET;ORAL | 011366 | NDA | Strongbridge US Inc. | 71090-001 | 71090-001-01 | 100 TABLET in 1 BOTTLE (71090-001-01) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 50MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | Yes | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 50MG | ||||
| Approval Date: | Aug 7, 2015 | TE: | RLD: | Yes | |||||
| Regulatory Exclusivity Expiration: | Aug 7, 2022 | ||||||||
| Regulatory Exclusivity Use: | TREATMENT OF PRIMARY HYPERKALEMIC PERIODIC PARALYSIS, PRIMARY HYPOKALEMIC PERIOD PARALYSIS, AND RELATED VARIANTS | ||||||||
Complete Access Available with Subscription
